Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment
Although immune checkpoint inhibitors have opened a new mode of treatment for solid tumors, their efficacy in nasopharyngeal carcinoma (NPC) needs to be further investigated. Inhibitors of the PD-1/PD-L1 immune checkpoint are one of the hot topics in tumor immunotherapy. Programmed death ligand-2 (P...
Gespeichert in:
Veröffentlicht in: | Journal of Cancer 2022-01, Vol.13 (15), p.3606-3614 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3614 |
---|---|
container_issue | 15 |
container_start_page | 3606 |
container_title | Journal of Cancer |
container_volume | 13 |
creator | Li, Aixin Wu, Weijun Deng, Shengling Yang, Qiao He, Junyan Wu, Haibiao Wang, Haiyun Zhang, Jiaxing Feng, Qisheng Shao, Jianyong Zeng, Yixin Cai, Manbo |
description | Although immune checkpoint inhibitors have opened a new mode of treatment for solid tumors, their efficacy in nasopharyngeal carcinoma (NPC) needs to be further investigated. Inhibitors of the PD-1/PD-L1 immune checkpoint are one of the hot topics in tumor immunotherapy. Programmed death ligand-2 (PD-L2) is a less studied ligand of PD-1 and has not yet been fully explored, especially in NPC. Understanding the clinical significance of PD-L2 expression, together with immune cell infiltration, might provide clues for biomarker screening in NPC immunotherapy. This study aimed to evaluate the role of PD-L2 as a prognostic factor for NPC patients as well as its role in immune regulation.
Immunohistochemistry (IHC) was performed on a tissue microarray including 557 NPC specimens using PD-L2 antibody. The immune cell markers CD4, FOXP3 and CD68 were also stained and quantified. The expression of PD-L2 exhibited different spatial patterns among NPC tumor and stromal tissues.
A total of 90.8% of the cases showed membranous PD-L2 expression in tumors, and 80.8% showed membranous PD-L2 expression in stromal tissue. High stromal expression of PD-L2 predicted favorable overall and disease-free survival of NPC patients and was negatively correlated with tumor size, recurrence or metastasis and clinical stage. In contrast, high tumor abundance of PD-L2 correlated with poor disease-free survival, but had no obvious correlation with clinicopathological parameters. Multivariate analysis indicated that stromal PD-L2 was an independent and favorable prognostic factor. Furthermore, we found a positive correlation between stromal PD-L2 expression and the infiltration of CD68
macrophages and CD4
Foxp3
Treg cells in NPC stromal tissues (Pearson correlation=0.181 and 0.098, respectively).
Our results suggest that different PD-L2 expression patterns have distinct predictive values. PD-L2 expressed on stromal cells might play a role in the regulation of NPC progression, and involve in immune activation in the tissue microenvironment and have an independent good prognosis for NPC patients. |
doi_str_mv | 10.7150/jca.77643 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9809305</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2761987421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-8aa3ceccdc601a4e7079a3be586adc64db8710bee41a082f2c9ed9788b3ed3953</originalsourceid><addsrcrecordid>eNpdkU9P3DAQxa0KVBBw6BeoLHGhh4Ade2P7goQW-kda2h7aszVxZne9SuxgZ2n77estFAG-2PL7aebNPELecXau-IxdbBycK9VI8YYcci1UZZpG7j17H5CTnDesHGFqJcVbciCahjXcsEMy3vweE-bsY6BxSb-nuEowDNjRa4RpTRd-BaGrauozhZyj8zAV8Zcv2g4OMRfFB_oVchzXkP6EFUJP55CcD3EAeutdihjufYoDhumY7C-hz3jyeB-Rnx9vfsw_V4tvn77MrxaVk0xMlQYQDp3rXMM4SFRMGRAtznQD5U92rVactYiSA9P1snYGO6O0bgV2wszEEbl8qDtu2zKOK60T9HZMfigmbQRvXyrBr-0q3lujmRFsV-DssUCKd1vMkx18dtj3EDBus61V2aBWsuYFPX2FbuI2hTLejmJaKslloT48UGUfOSdcPpnhzO6itCVK-y_Kwr5_7v6J_B-c-Asbu5w6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2760847414</pqid></control><display><type>article</type><title>Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Li, Aixin ; Wu, Weijun ; Deng, Shengling ; Yang, Qiao ; He, Junyan ; Wu, Haibiao ; Wang, Haiyun ; Zhang, Jiaxing ; Feng, Qisheng ; Shao, Jianyong ; Zeng, Yixin ; Cai, Manbo</creator><creatorcontrib>Li, Aixin ; Wu, Weijun ; Deng, Shengling ; Yang, Qiao ; He, Junyan ; Wu, Haibiao ; Wang, Haiyun ; Zhang, Jiaxing ; Feng, Qisheng ; Shao, Jianyong ; Zeng, Yixin ; Cai, Manbo</creatorcontrib><description>Although immune checkpoint inhibitors have opened a new mode of treatment for solid tumors, their efficacy in nasopharyngeal carcinoma (NPC) needs to be further investigated. Inhibitors of the PD-1/PD-L1 immune checkpoint are one of the hot topics in tumor immunotherapy. Programmed death ligand-2 (PD-L2) is a less studied ligand of PD-1 and has not yet been fully explored, especially in NPC. Understanding the clinical significance of PD-L2 expression, together with immune cell infiltration, might provide clues for biomarker screening in NPC immunotherapy. This study aimed to evaluate the role of PD-L2 as a prognostic factor for NPC patients as well as its role in immune regulation.
Immunohistochemistry (IHC) was performed on a tissue microarray including 557 NPC specimens using PD-L2 antibody. The immune cell markers CD4, FOXP3 and CD68 were also stained and quantified. The expression of PD-L2 exhibited different spatial patterns among NPC tumor and stromal tissues.
A total of 90.8% of the cases showed membranous PD-L2 expression in tumors, and 80.8% showed membranous PD-L2 expression in stromal tissue. High stromal expression of PD-L2 predicted favorable overall and disease-free survival of NPC patients and was negatively correlated with tumor size, recurrence or metastasis and clinical stage. In contrast, high tumor abundance of PD-L2 correlated with poor disease-free survival, but had no obvious correlation with clinicopathological parameters. Multivariate analysis indicated that stromal PD-L2 was an independent and favorable prognostic factor. Furthermore, we found a positive correlation between stromal PD-L2 expression and the infiltration of CD68
macrophages and CD4
Foxp3
Treg cells in NPC stromal tissues (Pearson correlation=0.181 and 0.098, respectively).
Our results suggest that different PD-L2 expression patterns have distinct predictive values. PD-L2 expressed on stromal cells might play a role in the regulation of NPC progression, and involve in immune activation in the tissue microenvironment and have an independent good prognosis for NPC patients.</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.77643</identifier><identifier>PMID: 36606190</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Antibodies ; Biomarkers ; Cancer ; Chemotherapy ; Clinical significance ; Epstein-Barr virus ; Immunotherapy ; Ligands ; Medical prognosis ; Metastasis ; Ostomy ; Radiation therapy ; Research Paper ; Statistical analysis ; Survival analysis ; Throat cancer ; Tumors</subject><ispartof>Journal of Cancer, 2022-01, Vol.13 (15), p.3606-3614</ispartof><rights>The author(s).</rights><rights>2022. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-8aa3ceccdc601a4e7079a3be586adc64db8710bee41a082f2c9ed9788b3ed3953</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809305/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809305/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36606190$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Aixin</creatorcontrib><creatorcontrib>Wu, Weijun</creatorcontrib><creatorcontrib>Deng, Shengling</creatorcontrib><creatorcontrib>Yang, Qiao</creatorcontrib><creatorcontrib>He, Junyan</creatorcontrib><creatorcontrib>Wu, Haibiao</creatorcontrib><creatorcontrib>Wang, Haiyun</creatorcontrib><creatorcontrib>Zhang, Jiaxing</creatorcontrib><creatorcontrib>Feng, Qisheng</creatorcontrib><creatorcontrib>Shao, Jianyong</creatorcontrib><creatorcontrib>Zeng, Yixin</creatorcontrib><creatorcontrib>Cai, Manbo</creatorcontrib><title>Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Although immune checkpoint inhibitors have opened a new mode of treatment for solid tumors, their efficacy in nasopharyngeal carcinoma (NPC) needs to be further investigated. Inhibitors of the PD-1/PD-L1 immune checkpoint are one of the hot topics in tumor immunotherapy. Programmed death ligand-2 (PD-L2) is a less studied ligand of PD-1 and has not yet been fully explored, especially in NPC. Understanding the clinical significance of PD-L2 expression, together with immune cell infiltration, might provide clues for biomarker screening in NPC immunotherapy. This study aimed to evaluate the role of PD-L2 as a prognostic factor for NPC patients as well as its role in immune regulation.
Immunohistochemistry (IHC) was performed on a tissue microarray including 557 NPC specimens using PD-L2 antibody. The immune cell markers CD4, FOXP3 and CD68 were also stained and quantified. The expression of PD-L2 exhibited different spatial patterns among NPC tumor and stromal tissues.
A total of 90.8% of the cases showed membranous PD-L2 expression in tumors, and 80.8% showed membranous PD-L2 expression in stromal tissue. High stromal expression of PD-L2 predicted favorable overall and disease-free survival of NPC patients and was negatively correlated with tumor size, recurrence or metastasis and clinical stage. In contrast, high tumor abundance of PD-L2 correlated with poor disease-free survival, but had no obvious correlation with clinicopathological parameters. Multivariate analysis indicated that stromal PD-L2 was an independent and favorable prognostic factor. Furthermore, we found a positive correlation between stromal PD-L2 expression and the infiltration of CD68
macrophages and CD4
Foxp3
Treg cells in NPC stromal tissues (Pearson correlation=0.181 and 0.098, respectively).
Our results suggest that different PD-L2 expression patterns have distinct predictive values. PD-L2 expressed on stromal cells might play a role in the regulation of NPC progression, and involve in immune activation in the tissue microenvironment and have an independent good prognosis for NPC patients.</description><subject>Antibodies</subject><subject>Biomarkers</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical significance</subject><subject>Epstein-Barr virus</subject><subject>Immunotherapy</subject><subject>Ligands</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Ostomy</subject><subject>Radiation therapy</subject><subject>Research Paper</subject><subject>Statistical analysis</subject><subject>Survival analysis</subject><subject>Throat cancer</subject><subject>Tumors</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkU9P3DAQxa0KVBBw6BeoLHGhh4Ade2P7goQW-kda2h7aszVxZne9SuxgZ2n77estFAG-2PL7aebNPELecXau-IxdbBycK9VI8YYcci1UZZpG7j17H5CTnDesHGFqJcVbciCahjXcsEMy3vweE-bsY6BxSb-nuEowDNjRa4RpTRd-BaGrauozhZyj8zAV8Zcv2g4OMRfFB_oVchzXkP6EFUJP55CcD3EAeutdihjufYoDhumY7C-hz3jyeB-Rnx9vfsw_V4tvn77MrxaVk0xMlQYQDp3rXMM4SFRMGRAtznQD5U92rVactYiSA9P1snYGO6O0bgV2wszEEbl8qDtu2zKOK60T9HZMfigmbQRvXyrBr-0q3lujmRFsV-DssUCKd1vMkx18dtj3EDBus61V2aBWsuYFPX2FbuI2hTLejmJaKslloT48UGUfOSdcPpnhzO6itCVK-y_Kwr5_7v6J_B-c-Asbu5w6</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Li, Aixin</creator><creator>Wu, Weijun</creator><creator>Deng, Shengling</creator><creator>Yang, Qiao</creator><creator>He, Junyan</creator><creator>Wu, Haibiao</creator><creator>Wang, Haiyun</creator><creator>Zhang, Jiaxing</creator><creator>Feng, Qisheng</creator><creator>Shao, Jianyong</creator><creator>Zeng, Yixin</creator><creator>Cai, Manbo</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220101</creationdate><title>Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment</title><author>Li, Aixin ; Wu, Weijun ; Deng, Shengling ; Yang, Qiao ; He, Junyan ; Wu, Haibiao ; Wang, Haiyun ; Zhang, Jiaxing ; Feng, Qisheng ; Shao, Jianyong ; Zeng, Yixin ; Cai, Manbo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-8aa3ceccdc601a4e7079a3be586adc64db8710bee41a082f2c9ed9788b3ed3953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies</topic><topic>Biomarkers</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical significance</topic><topic>Epstein-Barr virus</topic><topic>Immunotherapy</topic><topic>Ligands</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Ostomy</topic><topic>Radiation therapy</topic><topic>Research Paper</topic><topic>Statistical analysis</topic><topic>Survival analysis</topic><topic>Throat cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Aixin</creatorcontrib><creatorcontrib>Wu, Weijun</creatorcontrib><creatorcontrib>Deng, Shengling</creatorcontrib><creatorcontrib>Yang, Qiao</creatorcontrib><creatorcontrib>He, Junyan</creatorcontrib><creatorcontrib>Wu, Haibiao</creatorcontrib><creatorcontrib>Wang, Haiyun</creatorcontrib><creatorcontrib>Zhang, Jiaxing</creatorcontrib><creatorcontrib>Feng, Qisheng</creatorcontrib><creatorcontrib>Shao, Jianyong</creatorcontrib><creatorcontrib>Zeng, Yixin</creatorcontrib><creatorcontrib>Cai, Manbo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Aixin</au><au>Wu, Weijun</au><au>Deng, Shengling</au><au>Yang, Qiao</au><au>He, Junyan</au><au>Wu, Haibiao</au><au>Wang, Haiyun</au><au>Zhang, Jiaxing</au><au>Feng, Qisheng</au><au>Shao, Jianyong</au><au>Zeng, Yixin</au><au>Cai, Manbo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>13</volume><issue>15</issue><spage>3606</spage><epage>3614</epage><pages>3606-3614</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Although immune checkpoint inhibitors have opened a new mode of treatment for solid tumors, their efficacy in nasopharyngeal carcinoma (NPC) needs to be further investigated. Inhibitors of the PD-1/PD-L1 immune checkpoint are one of the hot topics in tumor immunotherapy. Programmed death ligand-2 (PD-L2) is a less studied ligand of PD-1 and has not yet been fully explored, especially in NPC. Understanding the clinical significance of PD-L2 expression, together with immune cell infiltration, might provide clues for biomarker screening in NPC immunotherapy. This study aimed to evaluate the role of PD-L2 as a prognostic factor for NPC patients as well as its role in immune regulation.
Immunohistochemistry (IHC) was performed on a tissue microarray including 557 NPC specimens using PD-L2 antibody. The immune cell markers CD4, FOXP3 and CD68 were also stained and quantified. The expression of PD-L2 exhibited different spatial patterns among NPC tumor and stromal tissues.
A total of 90.8% of the cases showed membranous PD-L2 expression in tumors, and 80.8% showed membranous PD-L2 expression in stromal tissue. High stromal expression of PD-L2 predicted favorable overall and disease-free survival of NPC patients and was negatively correlated with tumor size, recurrence or metastasis and clinical stage. In contrast, high tumor abundance of PD-L2 correlated with poor disease-free survival, but had no obvious correlation with clinicopathological parameters. Multivariate analysis indicated that stromal PD-L2 was an independent and favorable prognostic factor. Furthermore, we found a positive correlation between stromal PD-L2 expression and the infiltration of CD68
macrophages and CD4
Foxp3
Treg cells in NPC stromal tissues (Pearson correlation=0.181 and 0.098, respectively).
Our results suggest that different PD-L2 expression patterns have distinct predictive values. PD-L2 expressed on stromal cells might play a role in the regulation of NPC progression, and involve in immune activation in the tissue microenvironment and have an independent good prognosis for NPC patients.</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>36606190</pmid><doi>10.7150/jca.77643</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1837-9664 |
ispartof | Journal of Cancer, 2022-01, Vol.13 (15), p.3606-3614 |
issn | 1837-9664 1837-9664 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9809305 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
subjects | Antibodies Biomarkers Cancer Chemotherapy Clinical significance Epstein-Barr virus Immunotherapy Ligands Medical prognosis Metastasis Ostomy Radiation therapy Research Paper Statistical analysis Survival analysis Throat cancer Tumors |
title | Expression of Programmed Death Ligand-2 is associated with Prognosis in Nasopharyngeal Carcinoma Microenviroment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A36%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20Programmed%20Death%20Ligand-2%20is%20associated%20with%20Prognosis%20in%20Nasopharyngeal%20Carcinoma%20Microenviroment&rft.jtitle=Journal%20of%20Cancer&rft.au=Li,%20Aixin&rft.date=2022-01-01&rft.volume=13&rft.issue=15&rft.spage=3606&rft.epage=3614&rft.pages=3606-3614&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.77643&rft_dat=%3Cproquest_pubme%3E2761987421%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2760847414&rft_id=info:pmid/36606190&rfr_iscdi=true |